Featured Research

from universities, journals, and other organizations

Low-Molecular-Weight Heparins Inhibit Tumor Growth, Study Shows

Date:
April 15, 2008
Source:
Roswell Park Cancer Institute
Summary:
Low-molecular-weight heparins block the formation of new blood vessels and prevent tumor growth, according to the results of a study. Angiogenesis -- the development of new blood vessels -- fuels cancer cell reproduction. The use of low-molecular-weight heparins (LMWHs) has been shown to extend survival in cancer patients by reducing the clotting action of blood. However, the mechanism is unclear.

Low-molecular-weight heparins block the formation of new blood vessels and prevent tumor growth, according to the results of a study by Michael Wong, MD, PhD, FRCPC, Department of Medicine, Roswell Park Cancer Institute (RPCI).

Angiogenesis − the development of new blood vessels − fuels cancer cell reproduction. The use of low-molecular-weight heparins (LMWHs) has been shown to extend survival in cancer patients by reducing the clotting action of blood. However, the mechanism is unclear.

This study tested the hypothesis that sequestering blood vessel growth factors, such as fibroblast growth factor (FGF), would interfere with angiogenesis and lead to tumor cell death. The hypothesis was tested in a model group of a highly vascularized tumors treated with varying amounts of heparin and LMWH and compared with a model group that was untreated.

Researchers report that LMWHs interfered with the signaling in the blood vessel growth pathway and significantly inhibited the growth of highly vascular tumors. This was in contrast to the non-treated model, which exhibited a large number of blood vessels and a well-constructed vasculature.

“This study indicated that low-molecular-weight heparins strip and sequester a blood vessel growth factor, in this case FGF, away from its receptor and reduce vascular tumor growth,” said Dr. Wong. “Heparins are already in clinical use and by elucidating the antitumor effects, we hope to have an immediate beneficial impact on cancer patients.”

The abstract “Low-molecular-weight heparins (LMWHs) inhibit tumor growth through the sequestration of angiogenic cytokines” was presented on April 13 at at the 2008 annual meeting of the American Association for Cancer Research in San Diego, CA.


Story Source:

The above story is based on materials provided by Roswell Park Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Roswell Park Cancer Institute. "Low-Molecular-Weight Heparins Inhibit Tumor Growth, Study Shows." ScienceDaily. ScienceDaily, 15 April 2008. <www.sciencedaily.com/releases/2008/04/080414212841.htm>.
Roswell Park Cancer Institute. (2008, April 15). Low-Molecular-Weight Heparins Inhibit Tumor Growth, Study Shows. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/04/080414212841.htm
Roswell Park Cancer Institute. "Low-Molecular-Weight Heparins Inhibit Tumor Growth, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2008/04/080414212841.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins